Circulating Tumor Cells as Potential Biomarkers in Bladder CancerAjjai Alva, Pamela L. Paris, Terence W. Friedlander et al.|The Journal of Urology|2015Cited by 88
MP50-06 MICROPAPILLARY DIFFERENTIATION VERSUS CONVENTIONAL UROTHELIAL CARCINOMA: EFFECTS OF NEOADJUVANT CHEMOTHERAPY AND CYSTECTOMY ON SURVIVALNoah Canvasser, Jeffrey S. Montgomery, Stephen Dailey et al.|The Journal of Urology|2014Cited by 3
MP63-02 A PHASE I/II TRIAL OF PREHABILITATION IN PATIENTS UNDERGOING CYSTECTOMY FOR BLADDER CANCERJeffrey S. Montgomery, Alon Z. Weizer, Todd M. Morgan et al.|The Journal of Urology|2016Cited by 2
1766 LENGTH OF STAY FOLLOWING RADICAL CYSTECTOMY: HOW LONG IS LONG ENOUGH?Sapan N. Ambani, Todd M. Morgan, Alon Z. Weizer et al.|The Journal of Urology|2013Cited by 2
PD31-03 IMPAIRMENT FREE SURVIVAL: A RELEVANT CLINICAL ENDPOINT FOR BLADDER CANCER PATIENTS UNDERGOING CYSTECTOMYCheryl Lee, Alon Z. Weizer, Stephanie Daignault‐Newton et al.|The Journal of Urology|2015Cited by 0